What is the difference between CO2 laser (NuV, Monalisa Touch) and erbium laser for vaginal treatment?
CO2 lasers (like NuV and MonaLisa Touch) and erbium lasers both treat vaginal atrophy and dryness, but they differ in the depth and type of tissue interaction. CO2 lasers penetrate deeper, while erbium lasers are more superficial and precise, with less heat spread.
Detailed Medical Explanation
CO2 lasers (such as MonaLisa Touch and NuV) and erbium lasers are both fractional laser technologies used for vaginal rejuvenation, but they work differently at a tissue level. CO2 lasers deliver energy that penetrates deeper into the vaginal mucosa, causing controlled thermal damage, which stimulates collagen production and tissue remodelling. This can be effective for severe atrophic changes but can cause more heat diffusion and downtime. Erbium:YAG lasers, in contrast, have a higher water absorption rate, making their energy more superficial, precise, and less likely to cause thermal damage to deeper tissues. This results in a gentler treatment with less downtime and lower risk of scarring. Both approaches can improve symptoms of genitourinary syndrome of menopause (GSM), such as dryness and irritation, but their safety and efficacy profiles differ. Current evidence is evolving, and while some women report significant symptom relief, large-scale, long-term studies are still limited. Always seek a consultation with a medical specialist. See further info at RCOG and NHS.
Clinical Context
Vaginal laser treatments are generally offered to postmenopausal women or those experiencing symptoms such as dryness, pain, or laxity that have not improved with other therapies. A full clinical assessment is essential to determine suitability, and patients should discuss expectations, risks, and alternatives. Treatment is usually carried out by trained gynaecologists or women’s health specialists. Patient experiences show improvement in symptoms, but it is important to note that not all women respond in the same way.
Evidence-Based Approaches
According to NICE and RCOG guidance, more research is needed on the long-term safety and efficacy of vaginal laser treatments. Current evidence suggests some benefit in symptom management, but these devices are not yet standard NHS treatments for GSM. Alternative approaches include vaginal oestrogen, lubricants, and non-hormonal therapies. For more, see BNF Menopause Treatment Summary and NICE menopause guidance.